Signos, the company behind the first FDA-cleared over-the-counter glucose monitoring system for weight management, has raised $20 million from GV (Google Ventures), Dexcom, and Blue Cross Blue Shield of Alabama. As part of the partnership, Signos will be available for purchase on Stelo.com, Dexcom’s direct-to-consumer CGM site.
The platform uses Dexcom’s Stelo glucose biosensor paired with Signos’ proprietary AI to score meals and activities based on how each user’s body actually responds – showing which foods drive glucose higher, which meals keep them in range, and how adjustments accumulate into lasting change. For GLP-1 users specifically, Signos positions itself as the metabolic self-knowledge layer that makes results maintainable beyond appetite suppression alone.
“The weight management category is being completely reimagined right now, and the approaches that will endure are the ones that combine the best of medication with the best of personalized data,” said CEO and founder Sharam Fouladgar-Mercer.
The BCBS Alabama investment via 450 Ventures is a meaningful payer signal – reflecting growing recognition that metabolic health tools represent a cost-effective path to better outcomes as GLP-1 medication costs pressure payer systems.
